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Introduction
The vascular system is the fi  rst functionally developed organ 
system during ontogeny. The development of blood vessels 
starts with differentiation of mesodermal precursor cells to-
ward endothelial cells (ECs), hematopoietic cells, and vascu-
lar smooth muscle cells. The fi  rst vascular plexus in embryos 
is formed by de novo aggregation of hemangioblasts (vascu-
logenesis). Thereafter, vessel growth mainly occurs by the 
sprouting of capillaries from preexisting vessels (angiogene-
sis; Risau, 1997; Carmeliet, 2000). Endothelial sprouting is 
a complex process that involves the increase of vascular per-
meability, vessel wall disassembly, degradation of the base-
ment membrane, migration and proliferation of ECs, and, 
fi  nally, the formation of a capillary lumen. The newly formed 
sprouts are subsequently stabilized by formation of cellular 
junctions, extracellular matrix deposition, and recruitment of 
perivascular cells (Pepper, 2001; Jain, 2003). Among other 
proteases, matrix metalloproteinases (MMPs) are required 
for proteolytic remodeling of the extracellular matrix. Degra-
dation of the EC basement membrane, as well as cleavage of 
helical interstitial collagens, is rate limiting for endothe  lial 
sprouting (Pepper, 2001; Seandel et al., 2001; Davis and 
 Senger,  2005).
Although angiogenic signaling through growth factors 
like VEGF or basic FGF and their receptors has been studied in 
great detail, the role of endothelial transcription factors orches-
trating the angiogenic response is less well understood. Genetic 
approaches suggested that transcription factors of the hypoxia-
inducible factor, Ets, Gata, Hox, Hey, SCL/Tal, and Smad fami-
lies are implicated in different stages of vascular development 
(Oettgen, 2001; Coultas et al., 2005). Recently, an increasing 
body of evidence associated members of the Activator Protein-1 
(AP-1) family of transcription factors either directly or by co-
operation with aforementioned factors with angiogenic responses 
and/or programs (Schorpp-Kistner et al., 1999; Gerald et al., 
2004; Zhang et al., 2004). AP-1 consists of homo- or hetero-
dimers of Jun (c-Jun, JunB, and JunD), Fos (c-Fos, FosB, Fra-1, 
and -2), and ATF (ATF-2, -3, -4, and ATFa) family members 
(Angel and Karin, 1991; Eferl and Wagner, 2003; Hess et al., 
2004). Although different Jun factors have been reported to reg-
ulate genes implicated in angiogenesis, like VEGF and MMPs 
(Schorpp-Kistner et al., 1999; Eferl and Wagner, 2003; Zhang 
et al., 2004), a direct link between endothelial Jun proteins and 
angiogenesis has thus far remained questionable. When the diff-
erent Jun members were deleted in mice, only JunB-defi  cient 
embryos displayed vascular abnormalities and died between 
embryonic day (E)8.5 and E10 because of placental failure 
(Schorpp-Kistner et al., 1999). Conditional gene targeting 
JunB is required for endothelial cell morphogenesis 
by regulating core-binding factor β
Alexander H. Licht,
1 Oliver T. Pein,
1 Lore Florin,
1  Bettina Hartenstein,
1 Hendrik Reuter,
2 Bernd Arnold,
3 Peter Lichter,
2 
Peter Angel,
1 and Marina Schorpp-Kistner
1
1Division of Signal Transduction and Growth Control, 
2Division of Molecular Genetics, and 
3Division of Molecular Immunology, German Cancer Research Center 
(Deutsches Krebsforschungszentrum), D-69120 Heidelberg, Germany
T
he molecular mechanism triggering the organiza-
tion of endothelial cells (ECs) in multicellular tubules 
is mechanistically still poorly understood. We dem-
onstrate that cell-autonomous endothelial functions of 
the AP-1 subunit JunB are required for proper endothe-
lial morphogenesis both in vivo in mouse embryos with 
endothelial-speciﬁ  c ablation of JunB and in in vitro angio-
genesis models. By cDNA microarray analysis, we identiﬁ  ed 
  core-binding factor β (CBFβ), which together with the 
Runx proteins forms the heterodimeric core-binding trans-
cription complex CBF, as a novel JunB target gene. In line 
with our ﬁ  ndings, expression of the CBF target MMP-13 
was impaired in JunB-deﬁ   cient ECs. Reintroduction of 
CBFβ into JunB-deﬁ  cient ECs rescued the tube formation 
defect and MMP-13 expression, indicating an important 
role for CBFβ in EC morphogenesis.
A.H. Licht and O.T. Pein contributed equally to this paper.
Correspondence to M. Schorpp-Kistner: marina.schorpp@dkfz.de
Abbreviations used in this paper: AP-1, activator protein-1; CBF, core-binding 
factor; ChIP, chromatin immunoprecipitation; CRE, cAMP responsive element; 
E, embryonic day; EC, endothelial cell; MMP, matrix metalloproteinase; TRE, 
12-O-tetradecanoylphorbol-13-acetate–responsive element.
The online version of this article contains supplemental material.JCB • VOLUME 175 • NUMBER 6 • 2006  982
  provided novel insight into the physiological processes regulated 
by JunB. Bone development (Hess et al., 2003; Kenner et al., 
2004) and adaptive and innate immunity (Hartenstein et al., 
2002; Nausch et al., 2006), as well as wound healing and epi-
dermal proliferation (Zenz et al., 2005; Florin et al., 2006), are 
affected by the loss of JunB. Furthermore, JunB-defi  cient mice 
develop a myeloproliferative disease similar to human chronic 
myeloid leukemia (Passegue et al., 2001).
We investigated the cell-autonomous role of JunB in EC 
function in vivo and in vitro. EC-specifi  c ablation of JunB re-
sulted in early embryonic lethality, underscoring an essential 
role for JunB in vessel development in vivo. We found that cap-
illary sprouting of JunB-defi  cient aortic explants was strongly 
diminished, underlining the crucial role of JunB as a regulator 
of angiogenic programs. Isolated ECs lacking JunB expression 
failed to form capillary-like structures when cultured on Matrigel. 
Using cDNA microarray analysis, we identifi  ed core-binding 
factor β (CBFβ) as a novel JunB target gene. Importantly, rein-
troduction of CBFβ alone rescued the tube formation defect of 
JunB-defi  cient ECs, implying a critical role for CBFβ in EC 
morphogenesis. In line with these fi  ndings, expression of the 
common AP-1 and CBF target metalloproteinase MMP-13 was 
impaired. Consequently, ECs isolated from MMP-13–defi  cient 
mice failed to form capillary-like networks on Matrigel, thus, 
recapitulating the phenotype of JunB-defi  cient ECs.
Results
Embryonic lethality caused by loss 
of JunB expression in ECs
JunB is expressed in ECs during vascular development (Schorpp-
Kistner et al., 1999). To investigate the cell-autonomous func-
tion of JunB in ECs, we generated mice that lack JunB expression 
specifi  cally in their ECs. Tie-2-Cre transgenic mice were crossed 
to junB −/fl  ox mice to generate a junB −/∆ allele in ECs (junB 
−/∆
EC). To better visualize ECs, the mice were crossed to Tie-2-
lacZ reporter mice. The Cre-mediated deletion of the junB  
locus was detected by PCR analysis (unpublished data). 
Coexpression of JunB and the EC marker CD31 was confi  rmed 
by immunofl  uorescence staining of control embryos (Fig. 1 B). 
In contrast, junB −/∆
EC embryos showed no JunB expression in 
blood vessels, whereas other cell types (e.g., neurons) retained 
JunB expression. These data confi  rm the effi  cient deletion of 
the fl  oxed allele, specifi  cally in ECs. Embryonic lethality was 
observed around E10 in junB −/∆
EC mice. The embryos were 
already severely retarded at E9.5 compared with controls (Fig. 
1 A). Embryos had not yet turned and displayed enlarged peri-
cardial sacs. At E10.5, control mice developed a highly orga-
nized vascular tree in the head region, whereas junB −/∆
EC 
embryos showed a disorganized vasculature with aberrantly 
branching and dilated vessels (Fig. 1 A). Additionally, the yolk 
Figure 1.  Endothelium-speciﬁ  c deletion of junB disrupts 
vascular development. junB −/∆
EC embryos were gener-
ated by mating Tie-2-Cre/junB +/− and junB ﬂ  ox mice. 
(A) All embryos carried a Tie-2-lacZ transgene to visualize 
ECs by LacZ activity. Control embryos developed a nor-
mal vascular system, whereas junB −/∆
EC embryos were 
retarded at E9.5, had an enlarged pericardium, and 
showed a disorganized vasculature. At E10.5, when con-
trol embryos had developed a vascular tree in the ce-
phalic region, junB −/∆
EC embryos showed hardly any 
capillary sprouting and dilated vessels. Highly branched 
vessel structures were formed in yolk sacs (ys) of control 
embryos at E10.5, whereas yolk sacs of junB −/∆
EC em-
bryos showed only a primitive vascular plexus. (B) Colo-
calization of JunB and CD31 was observed by 
immunoﬂ  uorescence staining. Control embryos expressed 
JunB in ECs, whereas in junB −/∆
EC embryos JunB was 
expressed in neurons (asterisk), but was absent from 
CD31-positive blood vessels. (right) Schematic view of 
an embryo is given to indicate analyzed area (boxed 
  region). Lu, lumen; nt, neural tube. Bars: (A) 250 μm; 
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sacs of junB −/∆
EC embryos showed marked defects in vascular 
remodeling, as vessels formed only a primitive vascular plexus. 
In contrast, a hierarchically organized vessel structure devel-
oped in control mice (Fig. 1 A). Interestingly, this phenotype 
closely resembled the vascular defects observed in the embryo 
proper of the complete junB knockout mice (Schorpp-Kistner 
et al., 1999). However, vascularization of the placenta was not 
impaired in junB −/∆
EC mice (Fig. S1, available at http://www.
jcb.org/cgi/content/full/jcb.200605149). These data defi  ne an 
important role for JunB in the endothelial lineage in vivo.
Capillary sprouting of aortic explants 
is severely impaired in JunB-deﬁ  cient mice
Because of the early embryonic death, it was diffi  cult to investi-
gate altered EC function in junB −/∆
EC mice. Therefore, we 
used a second transgenic mouse model with conditional inacti-
vation of JunB. In Collagen1α2-Cre/junB  −/∆ mice (junB 
−/∆
Coll), effi  cient recombination of the junB locus occurred in 
many cell types, as reported previously (Florin et al., 2006). In 
contrast to completely JunB-defi  cient mice, these animals were 
viable (Florin et al., 2006) because of the fact that the deletion 
of junB occurred at a later stage of embryonic development 
(around E14; unpublished data). Analysis of genomic DNA re-
vealed complete junB deletion in aortic tissue and isolated pri-
mary ECs of junB −/∆
Coll mice (Fig. 2 A). To prove loss of JunB 
expression on protein level, primary ECs were isolated from 
these mice. Expression of endothelial marker proteins was con-
fi  rmed by FACS analysis and immunofl  uorescence staining for 
CD31, endoglin (CD105), VEGFR-2, or VE-cadherin (Fig. 2 B 
and not depicted), demonstrating the isolation of a 94–98% pure 
population of ECs. Immunoblotting revealed that the JunB pro-
tein was indeed undetectable in junB −/∆
Coll ECs, whereas it 
was expressed in control ECs (Fig. 2 C).
To investigate whether junB −/∆
Coll mice have a defect in 
blood vessel growth, mouse aortic ring assays were performed 
with explanted tissue of control or junB −/∆
Coll aortae (Fig. 2 D). 
Within 7 d of explant culture, strong outgrowth of capillary 
sprouts from the aortic rings was observed in control (Fig. 2 D) 
or Tie-2-lacZ reporter mice. Staining for LacZ activity or 
 immunofl  uorescence staining for CD31 confi  rmed that these 
sprouts originate from ECs and that they form a vessel lumen 
(Fig. S2, A–E, available at http://www.jcb.org/cgi/content/full/
jcb.200605149). In contrast, junB −/∆
Coll rings showed nearly 
no capillary outgrowth (Fig. 2 D). To exclude that the effect is 
solely caused by paracrine VEGF acting on ECs, aortic ring as-
says were performed in the presence of exogenously added re-
combinant VEGF. In control aortae, the addition of VEGF to the 
medium did not further increase the already strong sprouting 
activity (Fig. 2 E), indicating that the VEGF levels in the me-
dium are already in a saturation range. In junB −/∆
Coll explants, 
additional VEGF had no effect on sprout formation (Fig. 2 E). 
Thus, VEGF is not the limiting factor for sprouting in this 
  system, and JunB most likely induces capillary growth via 
other mechanisms.
Impaired capillary-like tube formation 
of JunB-deﬁ  cient ECs
The capability of primary ECs to form tube-like structures was 
investigated upon cultivation on Matrigel (Fig. 3 A). Control 
ECs formed capillary-like structures that connected to anasto-
mosing networks within 18 h in culture. In sharp contrast, junB 
−/∆
Coll ECs largely failed to generate tubes, but instead formed 
cellular aggregates, even if cultured for longer time periods. 
Like in the aortic ring assay, addition of recombinant VEGF did 
not rescue the tube formation defect (unpublished data). Our 
fi  nding was supported by the use of a second model involving 
JunB-defi  cient transformed ECs, so-called endothelioma (END) 
cells that provide a model for activated embryonic endothelium 
(Reiss et al., 1998). Control END cells formed tubelike struc-
tures and networks of EC cords very rapidly (within 6 h) on 
Matrigel (Fig. 3 A). As observed for junB −/∆
Coll ECs, cord for-
mation of JunB-defi  cient END cells was drastically decreased 
(13% of the control cells), which was quantifi  ed by counting in-
terendothelial spaces (Fig. 3 C). A similar phenotype was ob-
served with END cells derived from junB fl  ox/fl  ox mice, in 
which the fl  oxed allele was deleted by transduction of a retro-
viral Cre expression vector (junB ∆/∆; Fig. 3 A, bottom). The 
fl  oxed allele was effi  ciently deleted ( 90%), as revealed by 
FACS analysis for IRES-eGFP expression (unpublished data) 
and PCR amplifi  cation of the recombined locus (Fig. 3 B). 
Figure 2.  Reduced sprouting of JunB-deﬁ  cient  aortic 
  explants. (A) Complete deletion of the junB locus was veri-
ﬁ  ed by PCR in aortae (Ao) or primary ECs of junB −/∆
coll 
mice. (B) FACS analysis for the endothelial marker CD105 
(red line) conﬁ  rmed the isolation of a >94% (M1) pure 
population of ECs. (C) Immunoblotting revealed complete 
loss of JunB in nuclear extracts of junB  −/∆
coll ECs. 
(D) Aortic ring assay was performed using control or 
junB −/∆
coll mice. Bar, 770 μm. (E) To enhance vascular 
density, the aortic explants were cultured in medium con-
taining 40 or 100 ng/ml recombinant VEGF. Under both 
conditions, vascular density was signiﬁ   cantly lower in 
junB −/∆
coll aortae compared with the controls. Error bars 
indicate the SD. *, P < 0.05.JCB • VOLUME 175 • NUMBER 6 • 2006  984
  Defective tube formation could be caused by a failure in prolife-
ration; thus, the proliferation rate of control and junB −/∆
Coll ECs 
was determined by BrdU incorporation and subsequent FACS 
analysis, which revealed no considerable difference (Fig. 3 D). 
Lateral migration was investigated by scratching EC mono-
layers and by monitoring wound closure after 24 and 48 h. A slight 
delay in wound closure was observed in JunB-defi  cient cells 
  after 48 h (Fig. 3 E); however, these small differences in migra-
tion alone cannot account for the severe defects in tube forma-
tion (Fig. 3 A). The expression levels of genes typically involved 
in angiogenesis were analyzed by RT-PCR. No differences in 
expression of angiopoietin-1 and -2 or their receptors tie-1 
and -2 were observed. Decreased VEGF levels were found, but 
the main signaling receptor, VEGFR-2, was unaffected. In addi-
tion, similar levels of the AP-1 family members c-Jun, c-Fos, 
and ATF-2 were detected in control and JunB-defi  cient ECs 
(unpublished data). Collectively, analysis of proliferation, migra-
tion, and expression of known angiogenic candidate genes did 
not reveal fi  rst signs for a mechanism that could explain the 
phenotype of JunB-defi  cient cells. Therefore, a systematic  approach 
was chosen to compare the gene expression profi  les of JunB-
defi  cient and control cells.
cDNA microarray analysis identiﬁ  es novel 
JunB target genes
To search for target genes affected by the loss of JunB in the 
  endothelium, large-scale comparative gene expression analysis 
was performed using cDNA microarray technology. JunB ex-
pression is highly up-regulated by hypoxia (Fig. 4 B); thus, 
a combinatorial analysis of gene expression was performed 
in control and JunB-defi  cient ECs cultured under normoxia 
or hypoxia. Under hypoxic conditions, 729 genes were up-
  regulated in control cells, whereas the expression of 956 genes 
was repressed. However, by comparing the expression profi  le of 
control with JunB-defi   cient cells under hypoxic conditions, 
only 23 genes were up-regulated and 16 genes were repressed in 
a strictly JunB-dependent manner. The newly identifi  ed JunB-
dependent genes (Table I) included transcription factors (CBFβ, 
LBP-1a, Creb3l2, Pou6f1, Klf16, and FoxJ2), factors involved 
in protein synthesis (Farsla, Aars, and Eif3s10), genes involved 
in intracellular traffi  cking (Tram1, Kif5b, and Myo1D), genes 
involved in cytoskeletal architecture (Nestin, Rhophilin-2, and 
Tbcd), and genes regulating apoptosis (Diablo and Nix) and 
 metabolism  (Acsl4, Aldh1b1, Fdft1, and Tgm2). 
CBF𝗃 is induced by hypoxia 
in a JunB-dependent manner
Of the newly identifi  ed JunB target genes, our attention was 
  attracted by CBFβ. AP-1 and CBF factors physically interact 
in a transcriptional complex and transactivate common target 
genes (Selvamurugan et al., 1998; Hess et al., 2001). CBFβ is 
the common partner of the Runt-related transcription factors 
(Runx). Real-time RT-PCR analysis confi  rmed the results from 
the microarray analysis, showing a 3.3-fold induction of CBFβ 
under hypoxia, which was lost in junB −/− END cells, as well 
as in Cre-transduced junB ∆/∆ cells (Fig. 4 A and not depicted). 
Induction of CBFβ correlated with that of JunB by hypoxia in 
END cells (Fig. 4 B). To confi  rm that CBFβ is a JunB target in 
vivo, bone marrow cells were isolated from control and JunB-
defi   cient mice. Indeed, CBFβ expression was considerably 
  reduced (by 60%) in the absence of JunB, as determined by 
real-time RT-PCR and Western blot analysis (Fig. 4 C). 
Moreover, immunofl  uorescence staining was performed on embryo 
sections of junB −/∆
EC and control embryos. CBFβ expression 
colocalized with CD31-positive vessels in control embryos, 
whereas no CBFβ signal was detected in vessels of junB −/∆
EC 
embryos (Fig. 4 D). To investigate whether CBFβ is a direct 
JunB target, the murine CBFβ promoter region was cloned and 
different fragments were fused to a luciferase reporter gene. 
Promoter analysis revealed three potential AP-1 binding sites 
(12-O-tetradecanoylphorbol-13-acetate–responsive elements 
[TREs]) in the distal promoter region (nt −1,496 to −1,061) 
and one TRE and two cAMP-responsive elements (CREs) in 
Figure 3.  Capillary-like tube formation is impaired in JunB-deﬁ  cient ECs. 
(A) Control primary ECs and END cells formed capillary-like networks 
when cultured on Matrigel for 18 or 6 h, respectively, whereas JunB-
  deﬁ  cient cells failed to form capillary-like structures under the same conditions. 
A similar phenotype was observed for junB ∆/∆ END cells in which the junB 
locus was recombined by retroviral Cre transduction in vitro. Bar, 670 μm. 
(B) PCR analysis revealed that the junB ﬂ  oxed allele was efﬁ  ciently deleted 
in END cells transduced with a retroviral Cre expression vector, but not in 
cells transduced with empty vector. (C) The degree of vascular organization 
of END cells was quantiﬁ   ed by counting interendothelial spaces. JunB-
  deﬁ  cient cells only achieved 13% of the network organization compared 
with control cells. (D) Proliferation was assessed by BrdU incorporation, 
which revealed no differences between control and junB −/∆ ECs. (E) EC 
monolayers were scratched and wound closure was monitored after 
24 and 48 h. JunB-deﬁ  cient cells showed slightly delayed wound closure 
after 48 h. Error bars indicate the SD. * P < 0.05.JUNB, CBFβ, AND ENDOTHELIAL CELL MORPHOGENESIS • LICHT ET AL. 985
the proximal promoter region (nt −1,127 to −251; Fig. 4 F, 
top). Coexpression of either the complete or proximal reporter 
constructs (nt −1,496 to −251 or −1,127 to −251) with a 
JunB expression vector in F9 teratocarcinoma cells already in-
creased promoter activity by threefold (Fig. 4 E, top). Coexpre-
ssion of JunB with the dimerization partners ATF-2 or c-Fos 
further increased CBFβ promoter activity four- or eightfold in-
duction, respectively, whereas expression of ATF-2 or c-Fos 
alone had no effect (Fig. 4 E, top). The region containing the 
three distal TREs alone (nt −1,496 to −1,061) showed hardly 
any activity in this assay (Fig. 4 E, bottom); therefore, we hy-
pothesized that JunB binding to the CBFβ promoter should 
take place at the proximal CREs and TRE. To fi  nally prove the 
physical interaction of JunB with the CBFβ promoter, chro-
matin immunoprecipitation (ChIP) analysis was performed in 
ECs in the absence or presence of CoCl2. Primers were 
 designed  to  amplify specifi  c regions of the CBFβ promoter 
(P1, P2, and P3) that contain the TRE and CREs for potential 
binding of JunB. We found JunB binding at the proximal CREs 
and TRE (Fig. 4 F, P1 and P2). This binding was strongly enhanced 
in CoCl2-treated cells. In contrast, no interaction was observed 
at the three distal TREs (P3), confi  rming the data of the lucif-
erase reporter assay (Fig. 4 E). To fi  nd the dimerization partner 
of JunB regulating CBFβ expression, ChIP analysis was per-
formed using antibodies against ATF-2, c-Fos, and Fra-1 that 
are expressed in ECs. We only detected a constitutive inter-
action of ATF-2 with the CBFβ promoter in uninduced and 
CoCl2-treated ECs (Fig. 4 F, bottom). The binding occurred at 
the proximal CREs and TRE (P1), in the same region where 
JunB binding was detected. No ATF-2 binding was found at the 
three distal TREs. We detected no interaction of c-Fos or Fra-1 
with the CBFβ promoter (unpublished data). These data 
Figure 4.  CBF𝗃 expression is regulated by JunB. (A) Real-time RT-PCR analysis revealed induction of CBFβ after 16 h hypoxia in control END cells. In 
JunB-deﬁ  cient END cells, CBFβ expression was not inducible by hypoxia. (B) Under the same conditions, JunB expression was up-regulated fourfold. Western 
blot analysis conﬁ  rmed induction of JunB on protein level after CoCl2 treatment. (C) Real-time RT-PCR and Western blot analysis revealed strongly di-
minished CBFβ expression in bone marrow cells of junB −/∆
coll mice compared with control mice. (D) Immunoﬂ   uorescence staining for CBFβ was 
  performed on sections of control or junB −/∆
EC embryos. CBFβ expression colocalized with CD31-positive vessels in control embryos, whereas no signal 
was detected in junB −/∆
EC embryos. Bar, 100 μm. nt, neural tube. Arrowheads indicate blood vessels. Adjacent sections of embryo shown in Fig.1 B 
were used. (E) Fragments of the CBFβ promoter (−1496/−251, −1127/−251, and −1496/−1061) fused to a luciferase reporter gene were cotrans-
fected with junB, ATF-2, or c-fos in F9 carcinoma cells. The proximal fragment harboring only the proximal CRE and TRE elements (−1127/−251) shows 
a similar activity as the reporter with both distal and proximal CRE and TRE sites (−1496/−251). Expression of JunB induced the promoter, whereas ATF-2 
or c-Fos had no effect. JunB in combination with either ATF-2 or c-Fos led to a strong transactivation of these two CBFβ promoter fragments, whereas 
  promoter activity of the reporter containing solely the distal TRE elements (−1496/−1061) was hardly detectable. (F) ChIP analysis of the CBFβ promoter 
was performed using antibodies for JunB or ATF-2. Speciﬁ  c primer sets were used to discriminate promoter elements (P1, P2, and P3). JunB binding to the 
CBFβ promoter was detected at the proximal CRE and TRE (P1 and P2) and was strongly enhanced in ECs treated with 200 μM CoCl2 for 4 h. Binding 
of ATF-2 also occurred at the proximal promoter region (P1), whereas no binding of JunB or ATF-2 was found at the distal TRE sites (P3). Error bars indicate 
the SD. *, P < 0.05.JCB • VOLUME 175 • NUMBER 6 • 2006  986
strongly suggest that either a JunB–JunB homodimer or a 
JunB–ATF-2 heterodimer regulates CBFβ expression in ECs 
in vivo.
CBF𝗃 expression in JunB-deﬁ  cient ECs 
rescues tube formation defects
To determine whether CBFβ is functionally implicated in 
the tube-forming process of ECs, we attempted to rescue the 
phenotype. By retroviral gene transfer CBFβ, JunB, or empty 
control vector (Fig. S3 A, available at http://www.jcb.org/cgi/
content/full/jcb.200605149) were reintroduced into JunB-
 defi  cient END cells. After culture in selective medium, >96% 
of the cells integrated the retroviral vector into their genome, 
as determined by FACS analysis for the coexpressed IRES-
GFP reporter (Fig. S3 B). Immunoblotting confi  rmed strong 
expression of CBFβ or JunB in transduced cells (Fig. S3 C). 
As expected, JunB-defi  cient END cells transduced with empty 
vector did not form capillary-like structures when cultured on 
Matrigel (Fig. 5 A). Tube formation was effi  ciently rescued 
by reexpression of JunB in END cells (Fig. 5 A). Most no-
tably, CBFβ expression also rescued tube formation in JunB-
defi  cient cells (Fig. 5 A). To quantify vascular organization in 
these experiments, the interendothelial spaces were counted, 
which revealed a signifi  cant difference between the END cells 
transduced with empty vector and those transduced with CBFβ 
or JunB, respectively (Fig. 5 B). These data underscore a func-
tional implication of CBFβ in the morphogenic process down-
stream of JunB.
Table I. Genes regulated by JunB and hypoxia in ECs
Gene Gene name Unigene No. JunB Hx Function
Mospd1 motile sperm domain containing 1 Mm.28236 6.5 2.9 Cytoskeleton
Cbfb core binding factor beta Mm.2018 6.5 2.0 Transcription
Cnot6l CCR4-NOT transcription compl. subunit 6-like Mm.28374 6.1 2.6 Transcription
Wdr26 WD repeat domain 26 Mm.289082 4.6 4.1 Signaling
Acsl4 acyl-CoA synthetase long chain family 4 Mm.143689 4.2 3.1 Metabolism
Rbmxrt RNA binding motif protein, X chromosome  Mm.24718 3.6 5.0 Apoptosis
D530031C13Rik RIKEN cDNA D530031C13 gene Mm.390454 3.5 3.9 unknown
Ubp1 (LBP-1a) upstream binding protein 1 Mm.28052 3.5 2.6 Transcription
Tpt1 tumor protein translationally controlled 1 Mm.296922 3.3 3.2 Signaling
Eif3s10 eukar. translation initiation factor 3, subunit 10 Mm.2238 3.2 2.3 Translation
Ncald neurocalcin delta Mm.283370 2.9 4.6 Signaling
Creb3l2 CRE-binding protein 3-like 2 Mm.169929 2.9 4.2 Transcription
Top2b topoisomerase II beta Mm.130362 2.9 2.3 Transcription
Phf17 PHD ﬁ  nger protein 17 Mm.286285 2.8 14.0 Transcription
Rhpn2 rhophilin-2 Mm.286600 2.5 2.9 Cytoskeleton
Nes nestin Mm.331129 2.5 2.5 Cytoskeleton
Scmh1 sex comb on midleg homologue 1 Mm.208924 2.4 3.8 Differentiation
Tram1 translocating chain-assoc. membrane protein 1 Mm.28765 2.4 2.1 Transport
AI848100 expressed sequence AI848100  Mm.170002 2.4 3.2 unknown
Arid2 AT rich interactive domain 2 Mm.17166 2.3 2.3 Transcription
Bnip3l (Nix) BCL2/adenovirus E1B interacting protein 3-like Mm.29820 2.2 2.4 Apoptosis
Kif5b kinesin family member 5B Mm.223744 2.2 4.5 Transport
Btbd1 BTB domain containing 1 Mm.71103 2.1 3.7 Differentiation
Tbcd tubulin-speciﬁ  c chaperone d Mm.23686 −11.2 −2.2 Cytoskeleton
2810428I15Rik RIKEN cDNA 2810428I15 gene Mm.28242 −7.7 −3.0 unknown
Diablo diablo homologue (smac) Mm.46716 −6.1 −2.5 Apoptosis
Myo 1D myosin 1 D Mm.151948 −5.9 −2.6 Transport
Pou6f1 POU domain, class 6, transcription factor 1 Mm.28825 −5.3 −4.0 Transcription
Aldh1b1 aldehyde dehydrogenase 1 family member B1 Mm.331583 −4.5 −29.8 Metabolism
Klf16 kruppel-like factor 16 Mm.41513 −4.4 −3.3 Transcription
3200001K10Rik RIKEN cDNA 3200001K10 gene Mm.304075 −4.2 −2.5 unknown
FoxJ2 forkhead box J2 Mm.87142 −3.9 −4.7 Transcription
2900070E19Rik RIKEN cDNA 2900070E19 gene Mm.29128 −3.0 −2.2 unknown
Tgm2 transglutaminase 2, c polypeptide Mm.330731 −3.0 −2.4 Metabolism
Fdft1 farnesyl diphosphate farnesyl transferase 1 Mm.343538 −2.8 −2.8 Metabolism
Farsla phenylalanine-tRNA synthetase-like, alpha subunit Mm.292517 −2.6 −2.1 Translation
6720457D02Rik RIKEN cDNA 6720457D02 gene Mm.102840 −2.3 −7.4 unknown
Aars alanyl-tRNA synthetase Mm.24174 −2.1 −4.0 Translation
Gspt1 G1 to S phase transition 1 Mm.325827 −2.1 −2.8 Translation
Control and JunB-deﬁ  cient END cells were kept under normoxic or hypoxic conditions for 16 h, and total RNA was isolated and subjected to microarray analysis. 
The table lists identiﬁ  ed genes differentially regulated by JunB and hypoxia. JunB, fold induction of genes in control versus JunB-deﬁ  cient END cells; Hx, fold induction 
of genes kept under hypoxia (1.5% O2) versus normoxia. All genes listed from Tbcd downward are repressed genes.JUNB, CBFβ, AND ENDOTHELIAL CELL MORPHOGENESIS • LICHT ET AL. 987
Reduced collagenase activity 
and expression in JunB-deﬁ  cient ECs
To mechanistically explain the observed defects in sprouting 
and tube formation of JunB-defi  cient cells, we studied the in-
vasive capacity of control and JunB-defi  cient ECs. The ECs 
were plated on type I collagen gel, and after 10–14 d control 
cells changed from polygonal to spindlelike morphology and 
invaded the gel underlying the monolayer. By focusing through 
the optical planes, cells underneath the monolayer were iden-
tifi  ed that displayed long cellular protrusions and fi  lopodia, 
indicating an invasive/angiogenic phenotype (Fig. 6 A). In 
contrast, JunB-  defi  cient cells formed a monolayer on top of 
the collagen, but failed to invade deeper into the gel (Fig. 6 A). 
To investigate the molecular basis of impaired invasion, super-
natants of control and junB −/∆
Coll ECs were analyzed for 
collagenolytic activity. In this assay, native helical collagen 
served as a substrate, which is cleaved only by MMP-8, -13, 
and -14. Supernatant of JunB-defi  cient ECs revealed a 40% 
decrease in overall collagenase activity (Fig. 6 B), suggesting 
that reduced collagenase activity accounts for the impaired EC 
sprouting. RT-PCR analysis revealed strongly reduced expres-
sion of not only MMP-13 but also MMP-2, a known JunB target 
gene (Bergman et al., 2003), in JunB-defi  cient ECs in comparison 
to control cells. In contrast, MMP-9 and -14 mRNA levels 
were not affected (Fig. 6 C), whereas MMP-8 expression was 
not detectable in cells of both genotypes (unpublished data). 
The reduced expression of MMP-2 and -13 was confi  rmed by 
real-time RT-PCR analysis (Fig. 6 D). MMP-13 represents a 
well-documented common target of AP-1 and CBF transcrip-
tion factors that can physically interact and cooperate in the 
transactivation of MMP-13 in osteoblastic cells   (Selvamurugan 
et al., 1998; Hess et al., 2001). We were able to confi  rm these 
fi  ndings in ECs (Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200605149).
The AP-1/CBF target gene MMP-13 
is required for tube formation
To unequivocally determine the function of MMP-13 in this 
process, primary ECs were isolated from mmp-13 −/− mice 
(Stickens et al., 2004; Hartenstein et al., 2006) and applied in a 
tube formation assay. Indeed, MMP-13–defi  cient ECs largely 
failed to form capillary-like networks on Matrigel (14% com-
pared with control cells), confi  rming an essential role of MMP-13 
in tube formation in our model system (Fig. 7, A and B).  Finally, 
we investigated MMP-13 expression in JunB-defi  cient END 
cells transduced with CBFβ. Although junB −/− END cells 
transduced with empty vector showed no MMP-13 expression, 
introduction of CBFβ strongly up-regulated MMP-13 expres-
sion (Fig. 7 C). Together, these fi  ndings suggest that the defects 
in tube formation and sprouting observed in JunB-defi  cient ECs 
are a consequence of impaired CBFβ expression,   resulting in 
reduced expression of proteases.
Discussion
Previously, we have reported critical functions for JunB in 
 controlling cytokine-regulated mesenchymal–epidermal inter-
actions in skin by regulating keratinocyte proliferation and dif-
ferentiation in both a paracrine and autocrine manner (Florin et 
al., 2004b, 2006). Very recently, we could demonstrate an 
  essential role for JunB in basal and hypoxia-mediated VEGF 
expression and tumor angiogenesis, implying a paracrine mech-
anism for fi  broblast or tumor cell–derived VEGF acting on 
the endothelium (unpublished data). As JunB is also highly ex-
pressed in ECs, in this study we specifi  cally addressed the EC-
intrinsic requirement of JunB and JunB-dependent genetic 
Figure 5.  Reexpression of JunB or CBF𝗃 in JunB-deﬁ  cient ECs rescues the 
tube formation defect. (A) JunB-deﬁ  cient END cells were transduced with retro-
virus containing empty vector, JunB, or CBFβ expression vectors. Capillary-like 
tube formation on Matrigel was restored by JunB or CBFβ expression, but 
not by the vector control. Bar, 590 μm. (B) Quantiﬁ  cation of the degree 
of vascular organization yields only 30% for cells transduced with empty 
  vector, but 80% for cells reexpressing CBFβ when compared with JunB-
transduced cells (100%). Error bars indicate the SD. *, P < 0.05.
Figure 6.  Impaired invasive capacity of JunB-deﬁ  cient ECs caused by 
  reduced MMP-13 expression. (A) Control ECs seeded on collagen gel 
changed their morphology and invaded the gel. Note the elongated cells 
extending ﬁ  lopodia (arrowheads). JunB-deﬁ  cient cells formed a conﬂ  uent 
monolayer on top of the collagen gel, but did not invade the gel. Bar, 230 μm. 
(B) Collagenase activity was determined in the supernatant of ECs. JunB-
deﬁ  cient ECs only showed 60% collagenolytic activity of control cells. (C) 
RT-PCR analysis revealed expression of MMP-2 and -13 is reduced in JunB-
deﬁ   cient END cells. (D) Real-time RT-PCR conﬁ   rmed a 50 and 70% 
down-regulation of MMP-2 or -13, respectively. Error bars indicate the SD. 
*, P < 0.05.JCB • VOLUME 175 • NUMBER 6 • 2006  988
programs. Indeed, JunB deletion in the endothelial lineage us-
ing Tie-2-Cre mice resulted in severe vascularization defects in 
the yolk sac and embryo proper and early embryonic death, sug-
gesting an EC-intrinsic role for JunB. Accordingly, sprout for-
mation of JunB-defi   cient aortic explants and capability of 
primary ECs lacking JunB to form capillary-like cords when 
cultivated on Matrigel was strongly impaired, even in the pres-
ence of excessive recombinant VEGF, excluding that limiting 
VEGF levels account for this phenotype.
In the search for JunB-dependent target genes implicated 
in EC morphogenesis, we focused on genes differentially ex-
pressed in JunB-defi  cient ECs kept under normoxic or hypoxic 
conditions compared with control cells to mimic a physiologi-
cal condition for angiogenesis induction. Applying stringent 
criteria for expression profi  ling, 23 up- and 16 down-regulated 
genes were identifi  ed to be dependent on JunB and hypoxia. 
These genes can functionally be grouped in cytoskeletal com-
ponents, transcription factors, translational factors, and genes 
implicated in apoptosis, cellular traffi  cking, or metabolism.
For example, the group of cytoskeletal genes includes 
nestin, which is an intermediate fi  lament protein that is highly 
expressed in neuronal stem cells, but also in activated ECs. As 
nestin expression is down-regulated in quiescent ECs, it was re-
cently designated as a specifi  c marker for angiogenic ECs and 
probably a modulator of cytoskeletal dynamics in activated ECs 
(Mokry et al., 2004). A second cytoskeletal gene found in our 
screen is rhophilin-2, which encodes a Rho-GTPase–binding 
protein that modulates Rho activity, and thereby infl  uences re-
arrangement of the actin cytoskeleton (Peck et al., 2002). Previ-
ously, it has been shown that Rho-mediated actin organization 
is essential for cord formation of angiogenic ECs (Hoang et al., 
2004; Liu and Senger, 2004). A second group of JunB target 
genes is comprised of transcriptional regulators, such as 
LBP-1a, which is a mammalian homologue of the grainyhead 
transcription factor family originally found in Drosophila 
 melanogaster and implicated in BMP-4 signaling. Interestingly, 
LBP-1a–defi  cient mice display a phenotype very similar to that 
of JunB knockout mice, as the embryos die at E10 and have 
  severe defects in the vascularization of placenta and yolk sac 
(Parekh et al., 2004). In summary, the physiological features of 
these identifi  ed target genes imply that JunB is required for the 
transition from quiescent to angiogenic endothelium.
Yet, we concentrated our analysis on another transcrip-
tional regulator found among the JunB-dependent genes, namely 
the CBFβ, which is the common heterodimerization partner of 
the Runx comprising the three α-subunits Runx-1 (CBFα-2 and 
AML-1), -2 (CBFα-1), and -3 (CBFα-3). The Runx–CBFβ 
  dimer binds to a specifi  c DNA sequence and, depending on the 
recruitment of coactivators or co-repressors, activates or sup-
presses the transcription of target genes, respectively (Blyth 
et al., 2005).
Inactivation of the runx genes in mice revealed essential 
functions in defi  nitive hematopoiesis (Runx-1), in bone for-
mation (Runx-2), or in epithelial and neuronal development 
(Runx-3). Runx-1–defi  cient embryos had a lower number of 
small capillaries in the hindbrain; moreover, vessels in the 
hindbrain, pericardium, and yolk sac showed less branching 
(Takakura et al., 2000).
Deletion of the CBFβ subunit disrupted normal hemato-
poiesis and caused embryonic lethality between E12.5 and 
E13.5. Transgenic CBFβ expression in the hematopoietic sys-
tem rescued embryonic lethality and revealed impaired bone 
formation in CBFβ-defi  cient mice (Speck and Gilliland, 2002; 
Blyth et al., 2005). Hemorrhages were observed in the cephalic 
and lumbar region of CBFβ-defi   cient embryos starting at 
E10.5. This was associated with perivascular edema and cell 
death in areas of actively growing capillaries. It was hypothe-
sized that CBFβ may play a role in certain aspects of vessel de-
velopment, although this was not tested directly (Wang et al., 
1996). Moreover, Runx-1 or CBFβ are frequent targets of chro-
mosomal translocation in humans, which account for 25% of 
adult acute myeloid leukemia. In junB −/∆
Coll mice, CBFβ ex-
pression was decreased in bone marrow, which is the major site 
of endogenous CBFβ expression in vivo. Interestingly, pheno-
types of CBFβ- and JunB-deficient mice exhibit striking 
  similarities. Mice with reduced JunB expression develop a 
  leukemia-like disease (Passegue et al., 2001) and have defects 
in bone formation (Hess et al., 2003; Kenner et al., 2004), pro-
viding further physiological evidence for a role of JunB in reg-
ulating CBFβ expression.
Our data point to an additional function of CBFβ in the 
hypoxia-response of ECs. ChIP analysis revealed that CBFβ is 
a direct target gene of JunB in ECs. We demonstrate that CBFβ 
is functionally important for EC morphogenesis, as reexpres-
sion of CBFβ in JunB-defi  cient ECs rescued tube formation on 
Matrigel. CBFβ, Runx-1, and -2 expression was reported in 
ECs (Namba et al., 2000; Sun et al., 2001; Iwatsuki et al., 2005). 
Figure 7.  Loss of MMP-13 in ECs causes failure in tube formation. 
(A) Although control ECs formed highly organized networks on Matrigel, 
MMP-13–deﬁ  cient ECs displayed a severely impaired capillary-like net-
work formation capability. Bar, 500 μm. (B) Quantiﬁ  cation   revealed 15% 
of vascular organization in mmp-13 −/− ECs, compared with 100% of 
control cells. (C) Reexpression of CBFβ in JunB-deﬁ  cient END cells up-regulates 
MMP-13 expression, whereas the vector control had no effect on MMP-13 
expression. Error bars indicate the SD. *, P < 0.05.JUNB, CBFβ, AND ENDOTHELIAL CELL MORPHOGENESIS • LICHT ET AL. 989
In line with our fi  ndings, a function of CBFβ in ECs has been 
proposed previously, as overexpression of a dominant-negative 
mutant of CBFβ inhibited EC tube formation in type I collagen 
gels (Namba et al., 2000). Similarly, loss of Runx-1, or a trun-
cated Runx-2 protein, perturbs tube formation on Matrigel 
(Iwatsuki et al., 2005; Sun et al., 2001).
CBF and AP-1 are known to cooperate in the transactiva-
tion of the metalloproteinase MMP-13 (Selvamurugan et al., 
1998; Porte et al., 1999; Hess et al., 2001). MMP-13 is an inter-
stitial collagenase able to degrade native fi  brillar collagens in 
the triple helical domain in vivo that is required for endochon-
dral bone formation and homeostasis (Inada et al., 2004; Stickens 
et al., 2004). Recent evidence points to a critical and specifi  c 
function of MMP-13 derived from activated stromal cells and 
infl  ammation-responsive hematopoietic cells at sites of tumor 
tissue (Egeblad and Werb, 2002; Mueller and Fusenig, 2004) 
and in the chick chorioallantoic membrane in response to angio-
genic factors (Seandel et al., 2001; Zijlstra et al., 2004). We 
provide experimental evidence that loss of EC-intrinsic MMP-13 
expression caused by junB ablation and, consequently, im-
paired CBFβ expression results in diminished collagenolytic 
activity of JunB-defi  cient ECs and failure in sprouting and 
tube formation. Accordingly, mmp-13 −/− ECs also exhibited 
strongly reduced tube formation on Matrigel, suggesting that 
loss of MMP-13 may account for the angiogenic defects in 
JunB-defi  cient ECs. Reexpression of CBFβ in JunB-defi  cient 
cells led them to regain MMP-13 expression and tube  formation. 
Thus, our data provide strong evidence for a regulatory JunB–
CBFβ–protease axis in the EC sprouting process. Interestingly, 
mmp-13 knockout mice display delayed enchondral ossifi  cation 
and reduced vessel ingrowth into the primary ossifi  cation center 
(Inada et al., 2004; Stickens et al., 2004), presumably caused by 
the reduced bioavailability of VEGF. It was concluded that 
MMP-13 produced by chondrocytes might be critical for the 
  release of matrix-bound VEGF. So far there exists only one study 
stressing an EC-intrinsic role for MMP-13 as an important 
  effector of nitric oxide-activated EC migration (Lopez-Rivera 
et al., 2005). Thus, our fi  ndings underscore the importance of 
MMP-13 in EC function, which may also contribute to the pheno-
type of MMP-13–defi  cient mice.
In conclusion, we demonstrate an essential cell-autono-
mous function of JunB in ECs and identify CBFβ as a novel 
JunB target. The fact that a common target of CBF and AP-1, 
MMP-13, is crucial for capillary-like tube formation suggests 
important tasks for CBFβ in diseased neovascularization such 
as cancer and retinopathy. Henceforth, it will be interesting to 
dissect not only the individual contribution of autocrine and 
paracrine pathways addressed by JunB but also JunB/CBFβ 
converging on commonly known, as well as yet to be defi  ned, 
targets. It is conceivable that these pathways may prove to be a 
promising target for antiangiogenic therapy in the future.
Materials and methods
Transgenic mice
The generation of junB +/− (Schorpp-Kistner et al., 1999), junB ﬂ  o x  
(Kenner et al., 2004), Tie-2-Cre (Constien et al., 2001), Collagen1α2-
Cre (Florin et al., 2004a, 2006), and mmp13 −/− mice (Stickens et al., 
2004) has been previously described. Tie-2-lacZ (Schlaeger et al., 1997) 
transgenic mice were provided by U. Deutsch (University of Berne, Berne, 
Switzerland). The Tie-2-Cre or Collagen1α2-Cre mice were crossed to 
junB +/− mice and their offspring were mated to junB ﬂ  ox/ﬂ  ox mice to 
obtain junB −/∆ mice. junB +/ﬂ  ox,  junB +/∆, junB −/ﬂ  ox,  or  junB 
+/+ mice were used as controls. For genotyping, genomic DNA was 
isolated and PCR was performed for the junB locus as previously de-
scribed (Schorpp-Kistner et al., 1999). Embryos were ﬁ  xed and stained 
for LacZ activity, as previously described (Licht et al., 2004). For image 
acquisition, a dissecting microscope (M 10; Leica) equipped with a 
PlanApo 1.0×/0.04 NA objective (Leica) and a digital camera 
(DXM1200; Nikon) were used. Images were processed with Photoshop 
CS software (Adobe).
All mice used in this study were housed in speciﬁ  c pathogen-free 
and light-, temperature- (21°C), and humidity-controlled (50–60% relative 
humidity) conditions. Food and water were available ad libitum. The pro-
cedures for performing animal experiments were in accordance with the 
principles and guidelines of the Arbeitsgemeinschaft der Tierschutz-
beauftragten in Baden-Württemberg (ofﬁ  cials for animal welfare) and were 
approved by the Regierungspräsidium Karlsruhe.
Cell culture and luciferase reporter gene assay
END cells were established by infection of ECs derived from midgestation 
embryos with the N-TKmT retrovirus, as previously described (Reiss et al., 
1998). END cells expressed endothelial marker genes (VE-cadherin, 
CD31, CD105, and VEGFR-2), as determined by immunoﬂ  uorescence 
staining or FACS analysis, and were able to endocytose DiI-acetyl-LDL 
  particles (CellSystems). For hypoxia treatment, END cells were placed in 
an   incubator with 1.5% O2 partial pressure (CB; Binder) for 16 h.
The murine CBFβ promoter (nt −1,496 to −251) was ampliﬁ  ed 
by PCR using the primers CBFβ1 and CBFβ2 (Table S1, available at 
http://www.jcb.org/cgi/content/full/jcb.200605149). The promoter was 
ligated to a tata-luciferase reporter plasmid (van Dam et al., 1998). F9 tera-
tocarcinoma cells were cultured and transiently transfected as   previously 
described (Hess et al., 2001). 1 μg CBFβ promoter fused to the luciferase 
reporter gene was cotransfected with 0.5 μg AP-1 expression plasmids 
(JunB, c-Fos, and ATF-2 under control of the Rous sarcoma virus promoter) 
and 0.05 μg renilla-luciferase for normalization. Cells were lysed and lu-
ciferase activity was determined using the Dual-Luciferase   reporter system 
(Promega) and a Sirius luminometer (Berthold).
Isolation of primary ECs
Microvascular ECs were isolated from mouse lungs using a magnetic cell 
separation method, as previously described (Dong et al., 1997). In brief, 
magnetic beads (Dynabeads; Dynal) were coated with anti-CD31 antibod-
ies (Mec13.3; BD Biosciences). Two mouse lungs of similar genotype were 
pooled, minced, and digested with collagenase A solution (Roche). Cells 
were incubated with anti-CD31–coated Dynabeads and separated in a 
magnetic ﬁ   eld. After washing away unbound cells, the beads were re-
leased by trypsin/EDTA treatment. Isolated ECs were analyzed for the ex-
pression of endothelial marker genes as described in Cell culture and 
luciferase reporter gene assay.
Mouse aortic ring assay
Aortic explants were prepared as previously described (Zhu and Nicosia, 
2002). Mouse aortae were dissected free from connective tissue, cut in 1–
2-mm pieces using a scalpel, and washed in ice-cold DME. For each tissue 
explant, a drop of 40 μl rat type I collagen (Serva) was placed into a cul-
ture dish. Aortic rings were placed into the droplet with ﬁ  ne forceps. After 
polymerization of the gel, the dishes were ﬁ  lled with culture medium (see 
Isolation of primary ECs) supplemented with 40 or 100 ng/ml recombinant 
VEGF-A164 (R&D Systems). Capillary sprouting was quantiﬁ  ed in a semi-
quantitative manner by classiﬁ  cation of aortic rings from 1 (no capillary 
sprouting) to 4 (strong outgrowth reaching the margins of the collagen 
  matrix). In each experiment, at least nine aortic rings of control and junB 
−/∆
Coll mice were scored, and the experiment was repeated four times.
In vitro angiogenesis and invasion assay
Matrigel (BD Biosciences) was mixed with an equal volume ice-cold DME. 
150 μl Matrigel solution was poured into 48-well plates and incubated for 
at least 6 h at 37°C. 3.5 × 10
4 cells were seeded on top of the gel and in-
cubated for 6–24 h. Capillary-like tube formation was quantiﬁ  ed by count-
ing interendothelial spaces in three randomly chosen optical ﬁ  elds. Each 
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For analysis of invasive capacity, ECs were seeded on a type I colla-
gen gel and grown to conﬂ  uency. After incubation for 10 d, the invasion 
of EC into the underlying collagen gel was assessed by microscopic obser-
vation of different focus planes. For image acquisition, an inverse light 
  microscope (DMIL; Leica) equipped with Plan Apo objectives (4×/0.1 NA 
and 10×/0.2 NA) and a DXM1200 digital camera were used. Images 
were processed with Photoshop CS software.
BrdU incorporation
Proliferation was assessed by BrdU incorporation and subsequent FACS 
analysis using the BrdU Flow kit (BD Biosciences) according to the instruc-
tions of the manufacturer. In brief, 10
5 ECs were seeded on 6-well plates 
and cultured for 24 h. Cells were incubated with medium containing BrdU 
for 2 h and subjected to the assay protocol.
Lateral migration assay
ECs were plated in 6-well dishes and grown to conﬂ  uency. The mono-
layer was wounded by scratching with a pipette tip and photographed. 
After 24 and 48 h, the wounded area was photographed again and the 
wound closure was measured using ImageJ software (National Institutes 
of Health).
Retroviral gene transfer
JunB or CBFβ coding sequences were ampliﬁ  ed by PCR using the primers 
junB1, junB2, CBFβ3, and CBFβ4 (Table S1). The fragments were inserted 
into the pMXpie vector. JunB-deﬁ  cient END cells were transduced with retro-
viral vectors as previously described (Cerwenka et al., 2000). In brief, 
  cellular supernatant containing viral particles was transferred to 8 × 10
4 
END cells in 24-well plates. Cells were transduced by spin infection (3 h; 
2,000 rpm) and thereafter cultured in selective media containing 3 μg/ml 
puromycin (Sigma-Aldrich). Efﬁ   ciency of retroviral infection was deter-
mined by FACS analysis of GFP reporter gene expression.
cDNA microarray analysis
Total RNA was extracted from END cells cultured under normoxic or hy-
poxic conditions (1.5% O2 for 16 h) using TRIZOL reagent as suggested by 
the manufacturer (Invitrogen). A collection of 15,247 sequences from em-
bryonic cDNA libraries was used to generate the 15K NIA cDNA micro-
array. Details on probe labeling, hybridization, data acquisition, and 
analysis were previously described (Florin et al., 2004b).
RT-PCR analysis
Total RNA was isolated from mouse tissue or cultured ECs using peqGold 
RNApure reagent (PEQLAB) according to the instructions of the manufacturer. 
RNA was reverse transcribed using AMV reverse transcriptase (Promega). 
cDNA was used for semiquantitative RT-PCR or quantitative real-time 
RT-PCR using Absolute QPCR SYBR Green mix (ABgene) and a thermal 
  cycler (iCycler; BioRad Laboratories) controlled by MyiQ software (BioRad 
Laboratories). Primer sequences for MMPs were previously described 
(Martinez et al., 2005). For primer sequences for β-tubulin, HPRT, CBFβ5 
and -6, and JunB 3 and 4 see Table S1.
Western blot analysis
Whole-cell extracts or nuclear extracts were prepared as previously de-
scribed (Andrecht et al., 2002). Proteins were separated by SDS-PAGE 
and transferred to nitrocellulose membrane. Immunodetection was per-
formed using an enhanced chemiluminescence system (Perkin Elmer Life 
Science) and the following primary antibodies: anti-JunB (1:500; N17; 
Santa Cruz Biotechnology, Inc.), anti-RCC1 (1:500; BD Biosciences), anti-
CBFβ (1:500; E20; Santa Cruz Biotechnology, Inc.), and anti-HSC70 
(1:10,000; Noventa).
Collagenase activity assay
Collagenolytic activity in supernatants of EC cultures was determined using 
the Collagenase Activity Assay kit (CHEMICON International, Inc.) accor-
ding to the instructions of the manufacturer. Equal numbers of control and 
JunB-deﬁ  cient cells were seeded and cultured for 24–48 h. 100 μl of the 
supernatant were then subjected to the assay protocol.
Immunoﬂ  uorescence staining
Cryosections were ﬁ  xed with acetone at −20°C and stained at RT, as pre-
viously described (Hartenstein et al., 2006). An epiﬂ  uorescence  micro-
scope (DMLB; Leica) equipped with PlanApo objectives (10×/0.4 NA, 
20×/0.7 NA, 40×/0.85 NA, and 63× oil/1.3 NA) was used. 
A DXM1200 digital camera was used for documentation, and images 
were processed with Photoshop CS software. The primary antibodies used 
were CD31 (BD Biosciences), JunB (210; Santa Cruz Biotechnology, Inc.), 
and CBFβ (E20; Santa Cruz Biotechnology, Inc.). The secondary anti-
bodies used were goat anti–rat–Alexa Fluor 488 (Invitrogen) and goat 
anti–rabbit–Cy3 (Dianova).
ChIP Assay
A ChIP kit (Millipore) was used according to the instructions of the manu-
facturer. The antibodies used (all from Santa Cruz Biotechnology, Inc.) 
were JunB (c11), ATF-2 (c19), Fra-1 (N17), and c-Fos (4). For primer 
  sequences for the ampliﬁ  cation of the CBFβ promoter see Table S1.
In brief, 2.5 × 10
6 END cells were incubated with 200 μM CoCl2 
for 4 h. Cells were cross-linked in 1% formaldehyde for 20 min at RT. Cells 
were washed and sonicated using a Bioruptor device (Diagenode). Immuno-
precipitation was performed using protein A–Agarose. After washing, 
  protein–DNA complexes were eluted and cross-links were reversed. 
  Proteins were digested by proteinase K and DNA was extracted using 
QIAquick spin columns (QIAGEN).
Statistical analysis
The SD is indicated by error bars. Unpaired two-tailed t tests were 
  performed using Sigma Plot 8.0 software. Signiﬁ  cance was assumed for 
P values (P < 0.05; indicated by asterisks).
Online supplemental material
Table S1 shows details on PCR primer sequences. Fig. S1 shows the inves-
tigation of placental development, Fig. S2 shows the microscopic evalua-
tion of aortic ring assays, Fig. S3 shows the validation of retroviral gene 
transfer, and Fig. S4 shows mmp-13 promoter analysis in ECs.
The authors thank U. Deutsch and A. Cerwenka for providing transgenic mice 
and retroviral vectors, respectively, M. Hahn for advice on DNA microarrays, 
M. Sator-Schmitt, B. Vonderstrass, and S. Teurich for technical assistance, and 
J. Hess for providing mmp-13 reporter constructs and CBF expression plasmids 
and critically reading the manuscript.
This work was supported by the Deutsche Forschungsgemeinschaft 
(AN 182/8-2 and Transregio SFB23; B. Arnold, P. Angel, and M. Schorpp-
Kistner) and the Bundesministerium für Bildung und Forschung (NGFN2: SMP 
RNA 01GR0418, BTN 01GS0460 to P. Lichter)
Submitted: 23 May 2006
Accepted: 31 October 2006
References
Andrecht, S., A. Kolbus, B. Hartenstein, P. Angel, and M. Schorpp-Kistner. 2002. 
Cell cycle promoting activity of JunB through cyclin A activation. J. Biol. 
Chem. 277:35961–35968.
Angel, P., and M. Karin. 1991. The role of Jun, Fos and the AP-1 complex 
in cell-proliferation and transformation. Biochim. Biophys. Acta. 
1072:129–157.
Bergman, M.R., S. Cheng, N. Honbo, L. Piacentini, J.S. Karliner, and D.H. 
Lovett. 2003. A functional activating protein 1 (AP-1) site regulates ma-
trix metalloproteinase 2 (MMP-2) transcription by cardiac cells through 
interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem. J. 
369:485–496.
Blyth, K., E.R. Cameron, and J.C. Neil. 2005. The RUNX genes: gain or loss of 
function in cancer. Nat. Rev. Cancer. 5:376–387.
Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 
6:389–395.
Cerwenka, A., A.B. Bakker, T. McClanahan, J. Wagner, J. Wu, J.H. Phillips, and 
L.L. Lanier. 2000. Retinoic acid early inducible genes defi  ne a ligand 
family for the activating NKG2D receptor in mice. Immunity. 12:721–727.
Constien, R., A. Forde, B. Liliensiek, H.J. Grone, P. Nawroth, G. Hammerling, 
and B. Arnold. 2001. Characterization of a novel EGFP reporter mouse 
to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. 
Genesis. 30:36–44.
Coultas, L., K. Chawengsaksophak, and J. Rossant. 2005. Endothelial cells and 
VEGF in vascular development. Nature. 438:937–945.
Davis, G.E., and D.R. Senger. 2005. Endothelial extracellular matrix: biosyn-
thesis, remodeling, and functions during vascular morphogenesis and 
neovessel stabilization. Circ. Res. 97:1093–1107.
Dong, Q.G., S. Bernasconi, S. Lostaglio, R.W. De Calmanovici, I. Martin-
Padura, F. Breviario, C. Garlanda, S. Ramponi, A. Mantovani, and JUNB, CBFβ, AND ENDOTHELIAL CELL MORPHOGENESIS • LICHT ET AL. 991
A. Vecchi. 1997. A general strategy for isolation of endothelial cells from 
murine tissues. Characterization of two endothelial cell lines from the 
murine lung and subcutaneous sponge implants. Arterioscler. Thromb. 
Vasc. Biol. 17:1599–1604.
Eferl, R., and E.F. Wagner. 2003. AP-1: a double-edged sword in tumorigenesis. 
Nat. Rev. Cancer. 3:859–868.
Egeblad, M., and Z. Werb. 2002. New functions for the matrix   metalloproteinases 
in cancer progression. Nat. Rev. Cancer. 2:161–174.
Florin, L., H. Alter, H.J. Grone, A. Szabowski, G. Schutz, and P. Angel. 2004a. 
Cre recombinase-mediated gene targeting of mesenchymal cells. Genesis. 
38:139–144.
Florin, L., L. Hummerich, B.T. Dittrich, F. Kokocinski, G. Wrobel, S. Gack, 
M. Schorpp-Kistner, S. Werner, M. Hahn, P. Lichter, et al. 2004b. 
Identifi  cation of novel AP-1 target genes in fi  broblasts regulated during 
cutaneous wound healing. Oncogene. 23:7005–7017.
Florin, L., J. Knebel, P. Zigrino, B. Vonderstrass, C. Mauch, M. Schorpp-Kistner, 
A. Szabowski, and P. Angel. 2006. Delayed wound healing and epidermal 
hyperproliferation in mice lacking JunB in the skin. J. Invest. Dermatol. 
126:902–911.
Gerald, D., E. Berra, Y.M. Frapart, D.A. Chan, A.J. Giaccia, D. Mansuy, J. 
Pouyssegur, M. Yaniv, and F. Mechta-Grigoriou. 2004. JunD reduces 
tumor angiogenesis by protecting cells from oxidative stress. Cell. 
118:781–794.
Hartenstein, B., S. Teurich, J. Hess, J. Schenkel, M. Schorpp-Kistner, and P. 
Angel. 2002. Th2 cell-specifi  c cytokine expression and allergen-induced 
airway infl  ammation depend on JunB. EMBO J. 21:6321–6329.
Hartenstein, B., B.T. Dittrich, D. Stickens, B. Heyer, T.H. Vu, S. Teurich, M. 
Schorpp-Kistner, Z. Werb, and P. Angel. 2006. Epidermal development 
and wound healing in matrix metalloproteinase 13-defi  cient  mice. 
J. Invest. Dermatol. 126:486–496.
Hess, J., D. Porte, C. Munz, and P. Angel. 2001. AP-1 and Cbfa/runt physically 
interact and regulate parathyroid hormone-dependent MMP13 expression 
in osteoblasts through a new osteoblast-specifi  c element 2/AP-1 composite 
element. J. Biol. Chem. 276:20029–20038.
Hess, J., B. Hartenstein, S. Teurich, D. Schmidt, M. Schorpp-Kistner, and P. 
Angel. 2003. Defective endochondral ossifi  cation in mice with strongly 
compromised expression of JunB. J. Cell Sci. 116:4587–4596.
Hess, J., P. Angel, and M. Schorpp-Kistner. 2004. AP-1 subunits: quarrel and 
harmony among siblings. J. Cell Sci. 117:5965–5973.
Hoang, M.V., M.C. Whelan, and D.R. Senger. 2004. Rho activity critically and 
selectively regulates endothelial cell organization during angiogenesis. 
Proc. Natl. Acad. Sci. USA. 101:1874–1879.
Inada, M., Y. Wang, M.H. Byrne, M.U. Rahman, C. Miyaura, C. Lopez-Otin, and 
S.M. Krane. 2004. Critical roles for collagenase-3 (Mmp13) in develop-
ment of growth plate cartilage and in endochondral ossifi  cation. Proc. 
Natl. Acad. Sci. USA. 101:17192–17197.
Iwatsuki, K., K. Tanaka, T. Kaneko, R. Kazama, S. Okamoto, Y. Nakayama, Y. 
Ito, M. Satake, S. Takahashi, A. Miyajima, et al. 2005. Runx1 promotes 
angiogenesis by downregulation of insulin-like growth factor-binding 
protein-3. Oncogene. 24:1129–1137.
Jain, R.K. 2003. Molecular regulation of vessel maturation. Nat. Med. 
9:685–693.
Kenner, L., A. Hoebertz, T. Beil, N. Keon, F. Karreth, R. Eferl, H. Scheuch, 
A. Szremska, M. Amling, M. Schorpp-Kistner, et al. 2004. Mice lack-
ing JunB are osteopenic due to cell-autonomous osteoblast and osteoclast 
defects. J. Cell Biol. 164:613–623.
Licht, A.H., S. Raab, U. Hofmann, and G. Breier. 2004. Endothelium-
 specifi  c Cre recombinase activity in fl  k-1-Cre transgenic mice. Dev. Dyn. 
229:312–318.
Liu, Y., and D.R. Senger. 2004. Matrix-specifi  c activation of Src and Rho initi-
ates capillary morphogenesis of endothelial cells. FASEB J. 18:457–468.
Lopez-Rivera, E., T.R. Lizarbe, M. Martinez-Moreno, J.M. Lopez-Novoa, A. 
Rodriguez-Barbero, J. Rodrigo, A.P. Fernandez, A. Alvarez-Barrientos, 
S. Lamas, and C. Zaragoza. 2005. Matrix metalloproteinase 13 mediates 
nitric oxide activation of endothelial cell migration. Proc. Natl. Acad. Sci. 
USA. 102:3685–3690.
Martinez, C., S. Bhattacharya, T. Freeman, M. Churchman, and M. Ilyas. 2005. 
Expression profi   ling of murine intestinal adenomas reveals early de-
regulation of multiple matrix metalloproteinase (Mmp) genes. J. Pathol. 
206:100–110.
Mokry, J., D. Cizkova, S. Filip, J. Ehrmann, J. Osterreicher, Z. Kolar, and D. 
English. 2004. Nestin expression by newly formed human blood vessels. 
Stem Cells Dev. 13:658–664.
Mueller, M.M., and N.E. Fusenig. 2004. Friends or foes - bipolar effects of the 
tumour stroma in cancer. Nat. Rev. Cancer. 4:839–849.
Namba, K., M. Abe, S. Saito, M. Satake, T. Ohmoto, T. Watanabe, and Y. 
Sato. 2000. Indispensable role of the transcription factor PEBP2/CBF 
in angiogenic activity of a murine endothelial cell MSS31. Oncogene. 
19:106–114.
Nausch, N., L. Florin, B. Hartenstein, P. Angel, M. Schorpp-Kistner, and A. 
Cerwenka. 2006. Cutting edge: the AP-1 subunit JunB determines NK 
cell-mediated target cell killing by regulation of the NKG2D-ligand 
RAE-1epsilon. J. Immunol. 176:7–11.
Oettgen, P. 2001. Transcriptional regulation of vascular development. Circ. Res. 
89:380–388.
Parekh, V., A. McEwen, V. Barbour, Y. Takahashi, J.E. Rehg, S.M. Jane, and J.M. 
Cunningham. 2004. Defective extraembryonic angiogenesis in mice lack-
ing LBP-1a, a member of the grainyhead family of transcription factors. 
Mol. Cell. Biol. 24:7113–7129.
Passegue, E., W. Jochum, M. Schorpp-Kistner, U. Mohle-Steinlein, and E.F. Wagner. 
2001. Chronic myeloid leukemia with increased granulocyte progenitors in 
mice lacking junB expression in the myeloid lineage. Cell. 104:21–32.
Peck, J.W., M. Oberst, K.B. Bouker, E. Bowden, and P.D. Burbelo. 2002. The 
RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. 
J. Biol. Chem. 277:43924–43932.
Pepper, M.S. 2001. Role of the matrix metalloproteinase and plasminogen 
  activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 
21:1104–1117.
Porte, D., J. Tuckermann, M. Becker, B. Baumann, S. Teurich, T. Higgins, M.J. 
Owen, M. Schorpp-Kistner, and P. Angel. 1999. Both AP-1 and Cbfa1-
like factors are required for the induction of interstitial collagenase by 
parathyroid hormone. Oncogene. 18:667–678.
Reiss, Y., G. Hoch, U. Deutsch, and B. Engelhardt. 1998. T cell interaction 
with ICAM-1-defi  cient endothelium in vitro: essential role for ICAM-1 
and ICAM-2 in transendothelial migration of T cells. Eur. J. Immunol. 
28:3086–3099.
Risau, W. 1997. Mechanisms of angiogenesis. Nature. 386:671–674.
Schlaeger, T.M., S. Bartunkova, J.A. Lawitts, G. Teichmann, W. Risau, U. 
Deutsch, and T.N. Sato. 1997. Uniform vascular-endothelial-cell-specifi  c 
gene expression in both embryonic and adult transgenic mice. Proc. Natl. 
Acad. Sci. USA. 94:3058–3063.
Schorpp-Kistner, M., Z.Q. Wang, P. Angel, and E.F. Wagner. 1999. JunB is 
  essential for mammalian placentation. EMBO J. 18:934–948.
Seandel, M., K. Noack-Kunnmann, D. Zhu, R.T. Aimes, and J.P. Quigley. 2001. 
Growth factor-induced angiogenesis in vivo requires specifi  c cleavage of 
fi  brillar type I collagen. Blood. 97:2323–2332.
Selvamurugan, N., W.Y. Chou, A.T. Pearman, M.R. Pulumati, and N.C. 
Partridge. 1998. Parathyroid hormone regulates the rat collagenase-3 
promoter in osteoblastic cells through the cooperative interaction of the 
activator protein-1 site and the runt domain binding sequence. J. Biol. 
Chem. 273:10647–10657.
Speck, N.A., and D.G. Gilliland. 2002. Core-binding factors in haematopoiesis 
and leukaemia. Nat. Rev. Cancer. 2:502–513.
Stickens, D., D.J. Behonick, N. Ortega, B. Heyer, B. Hartenstein, Y. Yu, A.J. 
Fosang, M. Schorpp-Kistner, P. Angel, and Z. Werb. 2004. Altered en-
dochondral bone development in matrix metalloproteinase 13-defi  cient 
mice. Development. 131:5883–5895.
Sun, L., M. Vitolo, and A. Passaniti. 2001. Runt-related gene 2 in endothelial 
cells: inducible expression and specifi  c regulation of cell migration and 
invasion. Cancer Res. 61:4994–5001.
Takakura, N., T. Watanabe, S. Suenobu, Y. Yamada, T. Noda, Y. Ito, M. Satake, 
and T. Suda. 2000. A role for hematopoietic stem cells in promoting 
 angiogenesis.  Cell. 102:199–209.
van Dam, H., S. Huguier, K. Kooistra, J. Baguet, E. Vial, A.J. van der Eb, P. 
Herrlich, P. Angel, and M. Castellazzi. 1998. Autocrine growth and an-
chorage independence: two complementing Jun-controlled genetic pro-
grams of cellular transformation. Genes Dev. 12:1227–1239.
Wang, Q., T. Stacy, J.D. Miller, A.F. Lewis, T.L. Gu, X. Huang, J.H. Bushweller, 
J.C. Bories, F.W. Alt, G. Ryan, et al. 1996. The CBFbeta subunit is essen-
tial for CBFalpha2 (AML1) function in vivo. Cell. 87:697–708.
Zenz, R., R. Eferl, L. Kenner, L. Florin, L. Hummerich, D. Mehic, H. Scheuch, 
P. Angel, E. Tschachler, and E.F. Wagner. 2005. Psoriasis-like skin dis-
ease and arthritis caused by inducible epidermal deletion of Jun proteins. 
Nature. 437:369–375.
Zhang, G., C.R. Dass, E. Sumithran, N. Di Girolamo, L.Q. Sun, and L.M. 
Khachigian. 2004. Effect of deoxyribozymes targeting c-Jun on solid tumor 
growth and angiogenesis in rodents. J. Natl. Cancer Inst. 96:683–696.
Zhu, W.H., and R.F. Nicosia. 2002. The thin prep rat aortic ring assay: a modi-
fi  ed method for the characterization of angiogenesis in whole mounts. 
Angiogenesis. 5:81–86.
Zijlstra, A., R.T. Aimes, D. Zhu, K. Regazzoni, T. Kupriyanova, M. Seandel, 
E.I. Deryugina, and J.P. Quigley. 2004. Collagenolysis-dependent angio-
genesis mediated by matrix metalloproteinase-13 (collagenase-3). J. Biol. 
Chem. 279:27633–27645.